Topical Sirolimus for Microcystic Lymphatic Malformations

The purpose of this study is to evaluate thesafety and tolerability of the study drug PTX-022. The study will enroll maleand female patients between 13 and 60 years of age that have been diagnosedwith a microcystic lymphatic malformation with a history of frequent leakingand/or bleeding. Subjects will receive PTX-022, which is a topical gel that willbe applied directly to the lesion. Participation will last for about 20 weeksand will include 8 visits. Study visits include the following assessments:physical exams, vital signs, blood and urine tests, photography of the lesions,and the completion of diaries and questionnaires. Reimbursement for travel expensesand compensation for participation may be provided.